

# ACT Onco<sup>®</sup> + Report

PATIENT		
Name: 魏銘佐		Patient ID: 47987473
Date of Birth: Jan 06, 1998		Gender: Male
Diagnosis: Angiosarcoma		
ORDERING PHYSICIAN		
Name: 顏厥全醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11111272	Collection site: Pleural	Type: FFPE tissue
Date received: Mar 28, 2022	Lab ID: AA-22-01557	D/ID: NA

## ABOUT ACT Onco<sup>®</sup>+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) ( $\leq 15$  nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

## SUMMARY FOR ACTIONABLE VARIANTS

### VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

### VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
FLT4 Amplification	Pazopanib	-

#### Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

# ACT Onco<sup>®</sup> + Report

## TESTING RESULTS

### VARIANT(S) WITH CLINICAL RELEVANCE

#### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
<i>TP53</i>	V173del	83.4%

#### - Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr15	<i>NTRK3</i>	Amplification	6*
Chr4	<i>KDR</i>	Amplification	6*
Chr3	<i>RAF1</i>	Amplification	7*
Chr5	<i>FLT4</i>	Amplification	12

\* Increased gene copy number was observed.

#### - Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

#### - Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	1.2 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

#### Note:

- Variant(s) enlisted in the SNV table may currently exhibit no relevance to treatment response prediction. Please refer to INTERPRETATION for more biological information and/or potential clinical impacts of the variants.
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 71% tumor purity.
- TMB was calculated by using the sequenced regions of ACTOnco<sup>®</sup> to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at  $\geq 7.5$  mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is  $< 30\%$ .

# ACT Onco<sup>®</sup> + Report

## THERAPEUTIC IMPLICATIONS

### TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
<b>Level 4</b>		
<b>FLT4</b> Amplification	Pazopanib	<b>sensitive</b>

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
<b>1</b>	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
<b>2</b>	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
<b>3A</b>	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
<b>3B</b>	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
<b>4</b>	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

# ACT Onco<sup>®</sup> + Report

## IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

### - Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

## CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

## HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

## OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

### Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

# ACT Onco<sup>®</sup> + Report

## VARIANT INTERPRETATION

### TP53 V173del

#### Biological Impact

TP53 encodes the p53 protein, a crucial tumor suppressor that orchestrates essential cellular processes including cell cycle arrest, senescence and apoptosis<sup>[1]</sup>. TP53 is a proto-typical haploinsufficient gene, such that loss of a single copy of TP53 can result in tumor formation<sup>[2]</sup>.

TP53 V173del lies within the DNA-binding domain (DBD) of the p53 protein (UniProtKB). This mutation has not been characterized in scientific literature; therefore, its effect on the p53 protein function remains unknown.

#### Therapeutic and prognostic relevance

Despite having a high mutation rate in cancers, there are currently no approved targeted therapies for TP53 mutations. A phase II trial demonstrated that Wee1 inhibitor (AZD1775) in combination with carboplatin was well tolerated and showed promising anti-tumor activity in TP53-mutated ovarian cancer refractory or resistant (< 3 months) to standard first-line therapy (NCT01164995)<sup>[3]</sup>.

In a retrospective study (n=19), advanced sarcoma patients with TP53 loss-of-function mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with pazopanib<sup>[4]</sup>. Results from another Phase I trial of advanced solid tumors (n=78) demonstrated that TP53 hotspot mutations are associated with better clinical response to the combination of pazopanib and vorinostat<sup>[5]</sup>.

Advanced solid tumor and colorectal cancer patients harboring a TP53 mutation have been shown to be more sensitive to bevacizumab when compared with patients harboring wild-type TP53<sup>[6][7][8]</sup>. In a pilot trial (n=21), TP53-negative breast cancer patients demonstrated increased survival following treatment with bevacizumab in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel)<sup>[9]</sup>. TP53 mutations were correlated with poor survival of advanced breast cancer patients receiving tamoxifen or primary chemotherapy<sup>[10][11]</sup>. In a retrospective study of non-small cell lung cancer (NSCLC), TP53 mutations were associated with high expression of VEGF-A, the primary target of bevacizumab, offering a mechanistic explanation for why patients exhibit improved outcomes after bevacizumab treatment when their tumors harbor mutant TP53 versus wild-type TP53<sup>[12]</sup>.

### FLT4 Amplification

#### Biological Impact

The FLT4 (FMS-like tyrosine kinase 4) gene encodes for a vascular endothelial growth factor receptor 3 (VEGFR3), which involves in lymphangiogenesis and the maintenance of lymphatic endothelium<sup>[13]</sup>. VEGFR3 has been shown to mediate cell proliferation, survival, and chemoresistance in leukemia<sup>[14]</sup>, and to promote invasion and metastasis of human lung adenocarcinoma cells<sup>[15]</sup>. Mutations in FLT4 cause hereditary Nonne-Milroy disease, an autosomal dominant form of primary lymphedema type IA<sup>[16]</sup>. In addition to lymphatic endothelial cells, FLT4 is also expressed in lung adenocarcinoma<sup>[17]</sup>, colorectal adenocarcinoma<sup>[18]</sup>, head and neck carcinoma<sup>[19]</sup>, prostate carcinoma<sup>[20]</sup>, leukemia<sup>[14]</sup>, and Kaposi's sarcoma<sup>[21]</sup>. FLT4 expression levels were also shown to correlate with different stages of cervical carcinogenesis<sup>[22]</sup>.

#### Therapeutic and prognostic relevance

In a phase II trial of sorafenib in radiation-associated breast angiosarcomas, patients with co-amplification of MYC and FLT4 achieved complete or partial response (DOI: 10.1200/jco.2012.30.15\_suppl.10019). In clinical studies, a subset of patients with secondary angiosarcoma, mostly related to radiation-induced breast cancer and postlymphedema, co-harbored MYC and FLT4 amplification. The MYC and FLT4 amplification was associated to poor prognosis<sup>[23][24]</sup>. A case report showed that angiosarcoma patient with concurrent KDR and FLT4 amplification experienced a potent antitumor response and achieved clinically stable disease for 6 months after receiving pazopanib therapy<sup>[25]</sup>.

# ACT Onco<sup>®</sup> + Report

## KDR Amplification

### Biological Impact

KDR (kinase domain receptor), also known as VEGFR2 or Flk-1, is a tyrosine kinase receptor for the vascular endothelial growth factor (VEGF) and involves in angiogenesis pathway<sup>[26]</sup>. Binding of VEGF to KDR results in activation of phospholipase C (PLC-gamma) and downstream signaling via protein kinase C (PKC) and RAF/MEK/ERK<sup>[27]</sup>. Mutations of KDR are rare in tumors, and alterations of KDR activity typically occur via KDR amplification and subsequent overexpression<sup>[28][29]</sup>.

### Therapeutic and prognostic relevance

To date, there are four VEGF inhibitors (sorafenib, sunitinib, pazopanib, bevacizumab)<sup>[30][31]</sup> and one VEGFR2 inhibitor cabozantinib<sup>[32]</sup> that are FDA-approved for the treatment of cancers.

Notably, a case report showed that an angiosarcoma patient with concurrent KDR and FLT4 amplification developed a progressive disease when treated with sorafenib, but experienced a potent antitumor response and achieved clinically stable disease for 6 months after receiving pazopanib therapy<sup>[25]</sup>. Besides, an angiosarcoma patient with upregulated VEGFR2 responded to sunitinib treatment<sup>[33]</sup>.

VEGFR2 inhibitors like apatinib and vandetanib are in early clinical phase trial<sup>[34][35][36]</sup>.

The increased copy number of KIT or KDR significantly correlated with a worse 5-year breast cancer-specific survival (BCSS) in triple-negative breast cancer (TNBC) patients<sup>[37]</sup>.

KDR amplification and/or mutation has been selected as an inclusion criteria for the trial examining cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) (NCT04631744) and sunitinib in malignant solid tumors (NCT03297606).

## NTRK3 Amplification

### Biological Impact

The Neurotrophic Receptor Tyrosine Kinase Genes NTRK1, NTRK2, and NTRK3 encode tropomyosin receptor kinase (TRK) proteins TRKA, TRKB, and TRKC, respectively. NTRK3 can function as both oncogene and tumor-suppressor gene. Upon neurotrophin binding, NTRK3 initiates signaling cascades and leads to cell growth and differentiation. In the unbound state, NTRK3 induces apoptosis<sup>[38]</sup>.

Increased expression of NTRK3 has been identified in neuroblastomas, medulloblastomas and desmoplastic small round cell tumors<sup>[39][40][41]</sup>.

### Therapeutic and prognostic relevance

In a retrospective study, NTRK3 gene amplification has been demonstrated to associate with better prognosis in ovarian cancer patients treated with platinum-based chemotherapy. The median time to recurrence of patients with non-amplified NTRK3 (n=23) and amplified (n=18) were 5 and 18 months respectively. 12 cases without NTRK3 amplification were platinum-resistant recurrences (recurrence within 6 months) and 15 cases with NTRK3 amplification were platinum-sensitive (recurrence more than 6 months)<sup>[42]</sup>.

# ACT Onco<sup>®</sup> + Report

## RAF1 Amplification

### Biological Impact

The V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1 (RAF1) gene encodes a MAP kinase kinase kinase (MAP3K). There are three known mammalian Raf isoforms: A, B and C-Raf also called Raf-1 or c-Raf-1. Raf proteins and the MAPK pathway have been shown to play essential roles in various normal physiological processes as diverse as cellular metabolism, cell cycle progression, cell death and neurological functions<sup>[43]</sup>.

### Therapeutic and prognostic relevance

A clinical study has shown that RAF1 expression was associated with poor survival in high-grade serous subgroup ovarian cancer patients<sup>[44]</sup>. The hepatocellular carcinoma patients with higher expression of RAF1 who received postoperative adjuvant sorafenib had significantly longer overall survival than the group with lower expression of RAF1. However, the long-term tumor-free survival advantage disappeared<sup>[45]</sup>. In the E2603 trial, a retrospective analysis of melanoma patients (n=119) who received carboplatin, paclitaxel, and in combination with or without sorafenib (CPS), CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with RAF1 gene copy gains (HR = 0.372; P = 0.025)<sup>[46]</sup>.



# ACT Onco<sup>®</sup> + Report

## US FDA-APPROVED DRUG(S)

### Pazopanib (VOTRIENT)

Pazopanib is an oral, small molecule, multi-kinase inhibitor that targets receptor tyrosine kinase including vascular endothelial growth factor receptor-1, -2, -3 (VEGFR-1, -2, -3), platelet-derived growth factor receptor- $\alpha$ , - $\beta$  (PDGFR- $\alpha$ , - $\beta$ ), c-kit, fibroblast growth factor-1 and -3 (FGFR-1, -3), thereby inhibiting angiogenesis. Pazopanib is developed and marketed by GlaxoSmithKline under the trade name VOTRIENT.

### - FDA Approval Summary of Pazopanib (VOTRIENT)

<b>PALETTE<sup>[47]</sup></b> NCT00753688	<b>Sarcoma</b> (Approved on 2016/04/26)
	- Pazopanib vs. Placebo [PFS(M): 4.6 vs. 1.6]
<b>VEG105192<sup>[48]</sup></b> NCT00334282	<b>Renal cell carcinoma</b> (Approved on 2009/10/19)
	- Pazopanib vs. Placebo [PFS(M): 9.2 vs. 4.2]

D=day; W=week; M=month



# ACT Onco<sup>®</sup> + Report

## ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.

# ACT Onco<sup>®</sup> + Report


## SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
TP53	V173del	5	c.517_519del	NM_000546	-	83.4%	1033

### - Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



# ACT Onco<sup>®</sup> + Report

## OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ATR	H348N	4	c.1042C>A	NM_001184	-	90.1%	404
CTNNA1	V656I	14	c.1966G>A	NM_001903	-	62.9%	2242
KAT6A	P1799A	17	c.5395C>G	NM_006766	-	35.0%	748
KMT2C	Splice region	-	c.1012+4A>C	NM_170606	-	9.0%	3991
NTRK1	R342W	8	c.1024C>T	NM_002529	-	64.4%	693
PTCH1	Splice region	-	c.2560+7C>T	NM_000264	-	35.2%	1232
TSC2	R537C	16	c.1609C>T	NM_000548	-	50.1%	341


### Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

# ACT Onco<sup>®</sup> + Report

## TEST DETAILS

### SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Mar 2022
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11111272
- Collection site: Pleural
- Examined by: Dr. Chien-Ta Chiang
  1. The percentage of viable tumor cells in total cells in the whole slide (%): 25%
  2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 75%
  3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 40%
  4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
  5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

## RUN QC

- Panel: ACTOnco<sup>®</sup>+

### DNA test

- Mean Depth: 967x
- Target Base Coverage at 100x: 94%

### RNA test

- Average unique RNA Start Sites per control GSP2: 157

# ACT Onco<sup>®</sup> + Report

## LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

## NEXT-GENERATION SEQUENCING (NGS) METHODS

### DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage  $\geq 25$ , allele frequency  $\geq 5\%$  and actionable variants with allele frequency  $\geq 2\%$  were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at  $100\times \geq 85\%$  with a mean coverage  $\geq 500\times$ .

Variants reported in Genome Aggregation database with  $> 1\%$  minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation  $\geq 0.3$  were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco<sup>®</sup>+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to  $\geq 7.5$  mutations per megabase (Muts/Mb); TMB-Low corresponds to  $< 7.5$  Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is  $< 30\%$ .

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in  $> 400$  genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

### RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be  $\geq 10$ .

# ACT Onco<sup>®</sup> + Report

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2  $\geq 3$ ; (2) Number of supporting reads spanning the fusion junction  $\geq 5$ ; (3) Percentage of supporting reads spanning the fusion junction  $\geq 10\%$ ; (4) Fusions annotated in Quiver Gene Fusion Database.

## DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

## Variant Analysis:

醫檢師陳韻仔 博士  
Yun-Yu Chen Ph.D.  
檢字第 015647 號

Yun Yu Chen

## Sign Off

醫檢師陳韻仔 博士  
Yun-Yu Chen Ph.D.  
檢字第 015647 號

Yun Yu Chen

# ACT Onco<sup>®</sup> + Report

## GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTX	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBK	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLC01B1*
SLC01B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

\*Analysis of copy number alterations NOT available.

## FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------




# ACT Onco<sup>®</sup> + Report

## APPENDIX

### POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Not Applicable.

### SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Pazopanib; 2: Pazopanib; 3: Pazopanib; 4: Pazopanib; 5: Pazopanib

# ACT Onco<sup>®</sup> + Report

## DISCLAIMER

### 法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

### 醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

### 基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

### 證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

### 責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

# ACT Onco<sup>®</sup> + Report

## REFERENCE

1. PMID: 24739573; 2014, Nat Rev Cancer;14(5):359-70  
Unravelling mechanisms of p53-mediated tumour suppression.
2. PMID: 21125671; 2011, J Pathol;223(2):137-46  
Haplo-insufficiency: a driving force in cancer.
3. PMID: 27998224; 2016, J Clin Oncol;34(36):4354-4361  
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
4. PMID: 26646755; 2016, Ann Oncol;27(3):539-43  
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
5. PMID: 25669829; 2015, Ann Oncol;26(5):1012-8  
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
6. PMID: 27466356; 2016, Mol Cancer Ther;15(10):2475-2485  
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
7. PMID: 23670029; 2013, Oncotarget;4(5):705-14  
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
8. PMID: 17145525; 2006, Semin Oncol;33(5 Suppl 10):S8-14  
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
9. PMID: 21399868; 2011, Int J Oncol;38(5):1445-52  
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
10. PMID: 20549698; 2011, Int J Cancer;128(8):1813-21  
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
11. PMID: 10786679; 2000, Cancer Res;60(8):2155-62  
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
12. PMID: 25672981; 2015, Cancer Res;75(7):1187-90  
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.
13. PMID: 10762646; 2000, Int J Mol Med;5(5):447-56  
Signaling pathways induced by vascular endothelial growth factor (review).
14. PMID: 11877295; 2002, Blood;99(6):2179-84  
Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy.
15. PMID: 16530705; 2006, Cancer Cell;9(3):209-23  
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.
16. PMID: 11292664; 2001, FASEB J;15(6):1028-36  
VEGFR3 gene structure, regulatory region, and sequence polymorphisms.
17. PMID: 12875690; 2003, Chin Med J (Engl);116(5):727-30  
Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer.
18. PMID: 12168824; 2002, Anticancer Res;22(3):1463-6  
Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma.

# ACT Onco<sup>®</sup> + Report

19. PMID: 12784238; 2003, Head Neck;25(6):464-74  
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck.
20. PMID: 15701844; 2005, Clin Cancer Res;11(2 Pt 1):584-93  
Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
21. PMID: 10068212; 1999, Lab Invest;79(2):243-51  
Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells.
22. PMID: 14648657; 2003, J Pathol;201(4):544-54  
Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis.
23. PMID: 20949568; 2011, Genes Chromosomes Cancer;50(1):25-33  
Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions.
24. PMID: 26735859; 2016, Am J Surg Pathol;40(5):645-55  
Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.
25. PMID: 27160228; 2016, J Natl Compr Canc Netw;14(5):499-502  
Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.
26. PMID: 23172303; 2013, J Biochem;153(1):13-9  
Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
27. PMID: 12778165; 2003, Nat Med;9(6):669-76  
The biology of VEGF and its receptors.
28. PMID: 21382095; 2011, Neuropathology;31(6):583-8  
Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.
29. PMID: 31604903; 2020, Oncologist;25(1):e39-e47  
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
30. PMID: 23028128; 2012, Cold Spring Harb Perspect Med;2(10):  
Anti-VEGF therapies in the clinic.
31. PMID: 27718781; 2016, N Engl J Med;375(23):2246-2254  
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
32. PMID: 29972759; 2018, N Engl J Med;379(1):54-63  
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
33. PMID: 25639617; 2015, Breast J;21(2):205-7  
Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib.
34. PMID: 26578684; 2016, Clin Cancer Res;22(8):1940-50  
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
35. PMID: 29855279; 2018, BMC Cancer;18(1):618  
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report.
36. PMID: 31786466; 2020, Biomed Pharmacother;122():109587

# ACT Onco<sup>®</sup> + Report

Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.

37. PMID: 22170730; 2012, Genes Chromosomes Cancer;51(4):375-83  
Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis.
38. PMID: 23396845; 2013, Proc Natl Acad Sci U S A;110(8):2697-8  
Context is everything for dependence receptors in colorectal cancer.
39. PMID: 19417027; 2009, Clin Cancer Res;15(10):3244-50  
Trk receptor expression and inhibition in neuroblastomas.
40. PMID: 10694553; 2000, J Clin Oncol;18(5):1027-35  
TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors.
41. PMID: 33229458; 2021, Clin Cancer Res;27(4):1184-1194  
Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.
42. PMID: 28746220; 2017, Medicine (Baltimore);96(30):e7621  
Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.
43. PMID: 17555829; 2007, Biochim Biophys Acta;1773(8):1196-212  
Raf kinases: function, regulation and role in human cancer.
44. PMID: 16332724; 2006, Carcinogenesis;27(4):729-39  
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.
45. PMID: 26981887; 2016, Oncotarget;7(27):42598-42607  
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
46. PMID: 26307133; 2016, Clin Cancer Res;22(2):374-82  
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
47. PMID: 22595799; 2012, Lancet;379(9829):1879-86  
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
48. PMID: 20100962; 2010, J Clin Oncol;28(6):1061-8  
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.